This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2026 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.94% per year. These returns cover a period from January 1, 1988 through July 6, 2026. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View the Zacks #1 Rank List
Zacks News
5 Leveraged/Inverse ETFs That Gained More Than 40% in Q3
by Sweta Killa
The third quarter proved to be highly volatile and uncertain for the U.S. stock market.
5 Best Leveraged-Inverse ETFs of September
by Sweta Killa
September is on track to be the worst month of the year.
Best Inverse/Leveraged ETFs of Last Week
by Sanghamitra Saha
Wall Street delivered a downbeat show last week with the S&P 500 and Nasdaq logging worst weeks since March due to rising rate worries.
5 Inverse ETFs That Gained in Double Digits in August
by Sweta Killa
August was dull for Wall Street, with all three major indices finishing in the red. This resulted in huge demand for inverse or inverse-leveraged ETFs as these fetch outsized returns on bearish sentiments in a short span.
Inverse ETFs Soar as Market Turns Sour
by Sweta Killa
Wall Street has been caught in feeble trading in the past week, triggered by the U.S. credit rating downgrade and now bank downgrades. This has resulted in huge demand for inverse or inverse-leveraged ETFs.
5 Factors Why Inverse ETFs May Rule in 2H23
by Sanghamitra Saha
As short-sellers increase their bets against U.S. equities amidst a booming S&P 500 Index, we delve into why inverse ETFs may come to dominate the latter half of 2023.
5 Best Leveraged ETFs of Last Week
by Sanghamitra Saha
Wall Street was upbeat last week. Abating banking crisis and a less-hawkish Fed led to the rally in Wall Street.
ETF Winners From the Fed Meeting & Yellen's Testimony
by Sanghamitra Saha
Inverse ETFs surged yesterday despite the Fed's less-hawkish tone. Yellen's testimony probably have triggered the market selloffs.
5 Best Inverse-Leveraged ETFs of February
by Sweta Killa
Wall Street gave a dismal performance last month on Fed's longer-than-expected rate hike speculation, with all three major indices in red.
5 Least-Hurt Biotech ETFs of the Last Week
by Sanghamitra Saha
Rising rate worries have weighed on the biotech sector. However, these biotech ETFs still have lost the least in recent days.